Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.
AstraZeneca's Imfinzi receives EMA approval recommendation for NSCLC. AEGEAN trial shows significant recurrence reduction, enhancing patient outcomes and market potential.
AstraZeneca's Imfinzi receives EU approval as the first immunotherapy for LS-SCLC, showing significant survival benefits. This landmark decision highlights advancements in cancer care.
Explore AstraZeneca's recent MAA withdrawal for datopotamab deruxtecan, ongoing trials, and strategies in advancing lung cancer therapies.
AstraZeneca's Tagrisso receives EU approval for NSCLC, showing 39.1 months PFS in LAURA trial. A game-changer for lung cancer patients with EGFR mutations.
Explore Affimed N.V.'s latest 6-K filing detailing significant clinical trial updates for AFM24, safety profile, efficacy results, and a robust cash position projected into 2025.